唐人神(002567.SZ):4月生豬銷售收入合計7.62億元
格隆匯5月8日丨唐人神(002567.SZ)公佈,公司2025年4月生豬銷量43.52萬頭(其中商品豬41.55萬頭,仔豬1.97萬頭),2024年4月生豬銷量31.54萬頭(其中商品豬26.42萬頭,仔豬5.12萬頭),同比上升37.98%,環比上升7.48%;銷售收入合計76,219萬元,同比上升57.77%,環比上升10.98%。
2025年1-4月累計生豬銷量169.76萬頭(其中商品豬160萬頭,仔豬9.76萬頭),2024年1-4月累計生豬銷量126.24萬頭(其中商品豬109.4萬頭,仔豬16.84萬頭),同比上升34.47%;銷售收入294,479萬元,同比上升62.15%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.